Study to investigate the effectiveness and safety of Inj.Sepsivac in gram negative sepsis patients
Phase 4
- Conditions
- Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms
- Registration Number
- CTRI/2021/02/030882
- Lead Sponsor
- Medanta The Medicity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients presumed to have gram-negative sepsis(Clinically Diagnosed)
2.Age between 18 to 65 years (both inclusive)
3.Agrees to Provide Consent
Exclusion Criteria
1.History of allergic reactions attributed to Inj. Sepsivac® or any of its excipients
2. Pregnant and lactating women
3. Generalized septic skin conditions
4. Not willing to provide Consent
5. Patient not clinically diagnosed with Gram-ve sepsis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method